Harel Insurance Investments & Financial Services Ltd. Has $2.16 Million Holdings in Urogen Pharma $URGN

Harel Insurance Investments & Financial Services Ltd. cut its position in Urogen Pharma (NASDAQ:URGN) by 57.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 157,772 shares of the company’s stock after selling 216,210 shares during the period. Harel Insurance Investments & Financial Services Ltd. owned 0.34% of Urogen Pharma worth $2,161,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Allianz Asset Management GmbH bought a new stake in shares of Urogen Pharma during the second quarter worth approximately $203,000. Bender Robert & Associates bought a new stake in shares of Urogen Pharma during the second quarter worth approximately $475,000. Truist Financial Corp bought a new stake in shares of Urogen Pharma during the second quarter worth approximately $423,000. Jane Street Group LLC raised its stake in shares of Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after buying an additional 24,839 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Urogen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after buying an additional 2,983,368 shares during the last quarter. 91.29% of the stock is owned by institutional investors.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $20.47 on Friday. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.71. The company has a market capitalization of $946.94 million, a PE ratio of -6.17 and a beta of 1.00. The company has a 50 day moving average price of $18.47 and a two-hundred day moving average price of $14.72.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The firm had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. On average, sell-side analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Transactions at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the sale, the general counsel owned 43,305 shares of the company’s stock, valued at $827,558.55. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider directly owned 148,229 shares of the company’s stock, valued at $2,622,171.01. This represents a 6.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 14,594 shares of company stock valued at $259,713 over the last quarter. Corporate insiders own 4.70% of the company’s stock.

Wall Street Analyst Weigh In

URGN has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Urogen Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, October 18th. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Urogen Pharma in a research note on Monday, October 27th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Urogen Pharma in a research note on Monday, October 27th. Finally, Piper Sandler assumed coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Urogen Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.